Williams Jones & Associates LLC Has $3.56 Million Holdings in Henry Schein, Inc. (HSIC)
Williams Jones & Associates LLC reduced its position in Henry Schein, Inc. (NASDAQ:HSIC) by 6.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,469 shares of the company’s stock after selling 1,310 shares during the quarter. Williams Jones & Associates LLC’s holdings in Henry Schein were worth $3,563,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Henry Schein by 3.0% in the 2nd quarter. Vanguard Group Inc. now owns 8,086,317 shares of the company’s stock valued at $1,479,959,000 after buying an additional 236,862 shares in the last quarter. FMR LLC lifted its holdings in shares of Henry Schein by 0.4% during the 2nd quarter. FMR LLC now owns 6,921,367 shares of the company’s stock worth $1,266,749,000 after acquiring an additional 24,935 shares during the period. BlackRock Inc. lifted its holdings in shares of Henry Schein by 1.8% during the 2nd quarter. BlackRock Inc. now owns 5,696,685 shares of the company’s stock worth $1,042,607,000 after acquiring an additional 101,406 shares during the period. State Street Corp lifted its holdings in shares of Henry Schein by 1.3% during the 1st quarter. State Street Corp now owns 3,675,674 shares of the company’s stock worth $624,760,000 after acquiring an additional 48,469 shares during the period. Finally, Mackenzie Financial Corp lifted its holdings in shares of Henry Schein by 4.7% during the 1st quarter. Mackenzie Financial Corp now owns 1,728,230 shares of the company’s stock worth $293,747,000 after acquiring an additional 76,794 shares during the period. 44.52% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts recently issued reports on HSIC shares. Piper Jaffray Companies upgraded shares of Henry Schein from a “neutral” rating to an “overweight” rating in a research report on Friday, September 15th. Jefferies Group LLC restated a “hold” rating and set a $88.50 price objective on shares of Henry Schein in a research report on Friday, July 21st. Royal Bank Of Canada initiated coverage on shares of Henry Schein in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $91.00 price objective for the company. Zacks Investment Research cut Henry Schein from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Stifel Nicolaus restated a “hold” rating on shares of Henry Schein in a research note on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $92.85.
In related news, SVP Paul Rose sold 2,126 shares of the company’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $172.51, for a total value of $366,756.26. Following the completion of the transaction, the senior vice president now directly owns 17,841 shares in the company, valued at $3,077,750.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.27% of the company’s stock.
Shares of Henry Schein, Inc. (NASDAQ HSIC) traded up 0.21% during trading on Tuesday, reaching $81.20. The company’s stock had a trading volume of 249,057 shares. The stock has a market cap of $12.84 billion, a P/E ratio of 23.73 and a beta of 1.09. Henry Schein, Inc. has a 12-month low of $73.11 and a 12-month high of $93.50. The stock’s 50-day moving average is $83.87 and its 200-day moving average is $87.68.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.88 EPS for the quarter, topping the Zacks’ consensus estimate of $0.86 by $0.02. The firm had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.82 EPS. Equities research analysts anticipate that Henry Schein, Inc. will post $3.64 earnings per share for the current fiscal year.
Henry Schein declared that its Board of Directors has approved a share repurchase plan on Monday, September 18th that allows the company to buyback $400.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 6.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
Henry Schein Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.